Share Price and Basic Stock Data
Last Updated: October 26, 2025, 10:24 am
| PEG Ratio | 4.12 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
3B Blackbio DX Ltd, operating in the agrochemicals and pesticides sector, reported a share price of ₹1,387 with a market capitalization of ₹1,191 Cr. The company’s revenue from operations has shown variability, with sales standing at ₹12 Cr in June 2022, rising to ₹19 Cr by September 2023, before reaching ₹23 Cr in March 2024. However, the subsequent quarters indicate fluctuations, with a decline to ₹19 Cr in June 2024 followed by a rise to ₹29 Cr in September 2024. The overall trend in sales reflects the company’s ability to adapt to market demands, despite the challenges posed by seasonal fluctuations in the agricultural sector. Over the fiscal years, total sales rose from ₹22 Cr in March 2014 to ₹96 Cr by March 2025, demonstrating significant growth, especially in the recent fiscal year where sales rose from ₹62 Cr in March 2023 to ₹74 Cr in March 2024. This growth trajectory highlights the company’s strategic positioning in a competitive market.
Profitability and Efficiency Metrics
The profitability metrics of 3B Blackbio DX Ltd are commendable, with an operating profit margin (OPM) of 53%, indicating efficient cost management relative to its revenues. The company recorded a net profit of ₹48 Cr, reflecting a significant increase from ₹26 Cr in March 2023, which translates to an impressive net profit margin of 49.43% for the fiscal year ending March 2025. The earnings per share (EPS) stood at ₹55.66, showcasing robust profitability that aligns well with the company’s market performance. Moreover, the return on equity (ROE) was reported at 19.4%, while return on capital employed (ROCE) stood at 25.8%, indicating effective capital utilization. The interest coverage ratio (ICR) of 600.85x underscores the company’s strong ability to meet its interest obligations, bolstered by the absence of borrowings, which enhances its financial resilience. Furthermore, the cash conversion cycle of 235 days reflects a manageable efficiency in converting investments into cash flows.
Balance Sheet Strength and Financial Ratios
3B Blackbio DX Ltd exhibits a robust balance sheet with total reserves amounting to ₹260 Cr and zero borrowings, indicating a debt-free status that provides financial flexibility. The company’s total assets reached ₹296 Cr as of March 2025, with a current ratio of 7.11x and a quick ratio of 6.64x, reflecting strong liquidity positions. The price-to-book value (P/BV) ratio of 5.16x suggests a premium valuation in the market compared to its book value per share of ₹313.27. Furthermore, the company’s total debt to equity ratio stands at 0.00, reinforcing its solid capital structure. The efficiency ratios, including a return on assets (ROA) of 16.11%, indicate prudent asset management. The overall financial health of 3B Blackbio DX Ltd appears stable, with a sustainable growth model supported by retained earnings and a solid reserve base, positioning the company favorably against industry benchmarks.
Shareholding Pattern and Investor Confidence
The shareholding pattern of 3B Blackbio DX Ltd reveals a diverse ownership structure, with promoters holding 41.28% of the shares, reflecting a strong insider commitment to the company’s success. Foreign institutional investors (FIIs) accounted for 2.70%, while domestic institutional investors (DIIs) held 1.76%, indicating a modest level of institutional interest. Public shareholders constitute 54.28%, with the total number of shareholders reported at 10,619. This broad distribution suggests a healthy level of public engagement and investor confidence in the company’s growth prospects. Over the past few quarters, the percentage of promoter and FII holdings has remained relatively stable, while DII participation has seen slight increases, reflecting growing institutional confidence. The gradual decline in the number of shareholders from 15,415 in September 2022 to 10,619 indicates a consolidation phase, which could suggest a more concentrated investment base as the company continues to evolve.
Outlook, Risks, and Final Insight
If margins sustain at current levels, 3B Blackbio DX Ltd could leverage its strong profitability to enhance shareholder value through potential dividend declarations or reinvestments in business growth. However, risks include the inherent volatility in the agrochemicals market due to seasonality and regulatory changes that could impact operational efficiencies. Additionally, maintaining a high operating profit margin while managing costs effectively will be crucial in the face of fluctuating raw material prices. The company’s ability to innovate and adapt its product offerings to meet changing agricultural needs will also be vital for sustaining its growth trajectory. With a solid balance sheet and a commitment to shareholder returns, 3B Blackbio DX Ltd is strategically positioned to navigate challenges and capitalize on opportunities within the agrochemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of 3B Blackbio DX Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 7,359 Cr. | 1,706 | 2,243/1,502 | 17.1 | 441 | 0.35 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 992 Cr. | 294 | 391/165 | 19.0 | 117 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 56.3 Cr. | 108 | 148/55.2 | 10.3 | 34.1 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,223 Cr. | 249 | 392/234 | 113 | 53.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 796 Cr. | 337 | 670/244 | 11.6 | 320 | 0.89 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,396.20 Cr | 1,600.69 | 34.94 | 440.46 | 0.41% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 17 | 15 | 18 | 14 | 19 | 18 | 23 | 19 | 29 | 25 | 22 | 22 |
| Expenses | 7 | 8 | 7 | 11 | 8 | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 |
| Operating Profit | 5 | 9 | 7 | 7 | 6 | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 |
| OPM % | 44% | 53% | 50% | 41% | 45% | 41% | 50% | 43% | 56% | 55% | 59% | 35% | 53% |
| Other Income | 1 | 2 | 3 | 1 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | 11 | 10 | 8 | 9 | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 |
| Tax % | 24% | 23% | 22% | 38% | 22% | 26% | 24% | 36% | 21% | 23% | 24% | 36% | 20% |
| Net Profit | 5 | 8 | 8 | 5 | 7 | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 |
| EPS in Rs | 5.39 | 11.20 | 8.96 | 7.72 | 9.71 | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 |
Last Updated: August 20, 2025, 12:55 am
Below is a detailed analysis of the quarterly data for 3B Blackbio DX Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Expenses, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Jun 2025, the value is 53.00%. The value appears strong and on an upward trend. It has increased from 35.00% (Mar 2025) to 53.00%, marking an increase of 18.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 36.00% (Mar 2025) to 20.00%, marking a decrease of 16.00%.
- For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 14.67. The value appears strong and on an upward trend. It has increased from 9.79 (Mar 2025) to 14.67, marking an increase of 4.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:06 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 99 |
| Expenses | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 48 |
| Operating Profit | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 51 |
| OPM % | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 51% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 16 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 66 |
| Tax % | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | |
| Net Profit | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 49 |
| EPS in Rs | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 57.14 |
| Dividend Payout % | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 66.67% | 60.00% | 1325.00% | -71.93% | -18.75% | 23.08% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -6.67% | 1265.00% | -1396.93% | 53.18% | 41.83% | 26.92% |
3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 6% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 44% |
| 3 Years: | 14% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 32% |
| 3 Years: | 57% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: July 25, 2025, 2:02 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 |
| Borrowings | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 |
| Other Liabilities | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 |
| Total Liabilities | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 |
| Fixed Assets | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 |
| Other Assets | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 |
| Total Assets | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 |
Below is a detailed analysis of the balance sheet data for 3B Blackbio DX Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
- For Reserves, as of Mar 2025, the value is 260.00 Cr.. The value appears strong and on an upward trend. It has increased from 214.00 Cr. (Mar 2024) to 260.00 Cr., marking an increase of 46.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.00 Cr. (Mar 2024) to 27.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 296.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 248.00 Cr. (Mar 2024) to 296.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 39.00 Cr..
- For Other Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears strong and on an upward trend. It has increased from 123.00 Cr. (Mar 2024) to 132.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Mar 2025, the value is 296.00 Cr.. The value appears strong and on an upward trend. It has increased from 248.00 Cr. (Mar 2024) to 296.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (260.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.00 | -7.00 | -6.00 | -6.00 | -1.00 | 1.00 | 5.00 | 148.00 | 34.00 | 27.00 | 32.00 | 50.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 |
| Inventory Days | 120 | 145 | 143 | 175 | 164 | 141 | 124 | |||||
| Days Payable | 189 | 218 | 203 | 186 | 69 | 66 | 28 | |||||
| Cash Conversion Cycle | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 |
| Working Capital Days | 144 | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 |
| ROCE % | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 55.66 | 37.40 | 34.55 | 43.40 | 151.66 |
| Diluted EPS (Rs.) | 55.66 | 37.40 | 34.55 | 43.40 | 151.66 |
| Cash EPS (Rs.) | 56.93 | 38.70 | 35.77 | 43.88 | 152.82 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.27 | 263.15 | 261.50 | 229.69 | 197.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.27 | 263.15 | 261.50 | 229.69 | 197.92 |
| Revenue From Operations / Share (Rs.) | 112.59 | 86.51 | 82.54 | 107.65 | 302.66 |
| PBDIT / Share (Rs.) | 76.08 | 53.12 | 48.55 | 58.73 | 204.07 |
| PBIT / Share (Rs.) | 74.82 | 51.88 | 47.40 | 57.84 | 203.25 |
| PBT / Share (Rs.) | 74.69 | 51.74 | 47.13 | 57.69 | 202.94 |
| Net Profit / Share (Rs.) | 55.66 | 37.46 | 34.62 | 42.98 | 152.00 |
| NP After MI And SOA / Share (Rs.) | 55.61 | 37.46 | 34.62 | 42.98 | 152.00 |
| PBDIT Margin (%) | 67.57 | 61.40 | 58.81 | 54.56 | 67.42 |
| PBIT Margin (%) | 66.45 | 59.97 | 57.42 | 53.72 | 67.15 |
| PBT Margin (%) | 66.34 | 59.80 | 57.10 | 53.59 | 67.05 |
| Net Profit Margin (%) | 49.43 | 43.30 | 41.94 | 39.92 | 50.21 |
| NP After MI And SOA Margin (%) | 49.39 | 43.30 | 41.94 | 39.92 | 50.21 |
| Return on Networth / Equity (%) | 17.75 | 14.39 | 15.14 | 21.04 | 86.23 |
| Return on Capital Employeed (%) | 23.13 | 19.28 | 17.76 | 24.73 | 101.13 |
| Return On Assets (%) | 16.11 | 12.93 | 12.11 | 16.76 | 58.83 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.35 | 0.32 | 0.30 | 0.13 | 0.38 |
| Current Ratio (X) | 7.11 | 7.04 | 8.05 | 4.82 | 2.76 |
| Quick Ratio (X) | 6.64 | 6.56 | 7.49 | 4.38 | 2.64 |
| Inventory Turnover Ratio (X) | 3.03 | 2.41 | 2.33 | 2.66 | 2.68 |
| Interest Coverage Ratio (X) | 600.85 | 365.87 | 183.32 | 413.58 | 669.53 |
| Interest Coverage Ratio (Post Tax) (X) | 440.55 | 259.05 | 131.73 | 303.65 | 499.68 |
| Enterprise Value (Cr.) | 1319.35 | 600.55 | 278.94 | 248.35 | 196.43 |
| EV / Net Operating Revenue (X) | 13.68 | 8.10 | 4.51 | 3.08 | 0.86 |
| EV / EBITDA (X) | 20.24 | 13.19 | 7.67 | 5.64 | 1.28 |
| MarketCap / Net Operating Revenue (X) | 14.36 | 8.90 | 5.04 | 3.17 | 0.94 |
| Price / BV (X) | 5.16 | 2.96 | 1.82 | 1.67 | 1.62 |
| Price / Net Operating Revenue (X) | 14.36 | 8.90 | 5.04 | 3.17 | 0.94 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.12 | 0.53 |
After reviewing the key financial ratios for 3B Blackbio DX Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
- For Diluted EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
- For Cash EPS (Rs.), as of Mar 25, the value is 56.93. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 56.93, marking an increase of 18.23.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 112.59. It has increased from 86.51 (Mar 24) to 112.59, marking an increase of 26.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.08. This value is within the healthy range. It has increased from 53.12 (Mar 24) to 76.08, marking an increase of 22.96.
- For PBIT / Share (Rs.), as of Mar 25, the value is 74.82. This value is within the healthy range. It has increased from 51.88 (Mar 24) to 74.82, marking an increase of 22.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.69. This value is within the healthy range. It has increased from 51.74 (Mar 24) to 74.69, marking an increase of 22.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.61. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.61, marking an increase of 18.15.
- For PBDIT Margin (%), as of Mar 25, the value is 67.57. This value is within the healthy range. It has increased from 61.40 (Mar 24) to 67.57, marking an increase of 6.17.
- For PBIT Margin (%), as of Mar 25, the value is 66.45. This value exceeds the healthy maximum of 20. It has increased from 59.97 (Mar 24) to 66.45, marking an increase of 6.48.
- For PBT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has increased from 59.80 (Mar 24) to 66.34, marking an increase of 6.54.
- For Net Profit Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 10. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 49.39. This value exceeds the healthy maximum of 20. It has increased from 43.30 (Mar 24) to 49.39, marking an increase of 6.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has increased from 14.39 (Mar 24) to 17.75, marking an increase of 3.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has increased from 19.28 (Mar 24) to 23.13, marking an increase of 3.85.
- For Return On Assets (%), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.93 (Mar 24) to 16.11, marking an increase of 3.18.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.35. It has increased from 0.32 (Mar 24) to 0.35, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 7.11. This value exceeds the healthy maximum of 3. It has increased from 7.04 (Mar 24) to 7.11, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 6.64. This value exceeds the healthy maximum of 2. It has increased from 6.56 (Mar 24) to 6.64, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.03. This value is below the healthy minimum of 4. It has increased from 2.41 (Mar 24) to 3.03, marking an increase of 0.62.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 600.85. This value is within the healthy range. It has increased from 365.87 (Mar 24) to 600.85, marking an increase of 234.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 440.55. This value is within the healthy range. It has increased from 259.05 (Mar 24) to 440.55, marking an increase of 181.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,319.35. It has increased from 600.55 (Mar 24) to 1,319.35, marking an increase of 718.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 8.10 (Mar 24) to 13.68, marking an increase of 5.58.
- For EV / EBITDA (X), as of Mar 25, the value is 20.24. This value exceeds the healthy maximum of 15. It has increased from 13.19 (Mar 24) to 20.24, marking an increase of 7.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.96 (Mar 24) to 5.16, marking an increase of 2.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in 3B Blackbio DX Ltd:
- Net Profit Margin: 49.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.13% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.75% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 440.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 6.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.3 (Industry average Stock P/E: 34.94)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 49.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | 7-C, Industrial Area, Govindpura, Bhopal Madhya Pradesh 462023 | info@kilpest.com http://www.kilpest.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhirendra Dubey | Chairman & Managing Director |
| Mr. N K Dubey | Whole Time Director |
| CA. Shabbar Husain | Independent Director |
| Mr. Abdul Moin Khan | Independent Director |
| Mrs. Mithala Dubey | Director |
| Mr. Harihar Prasad Thapak | Independent Director |
FAQ
What is the intrinsic value of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd's intrinsic value (as of 26 October 2025) is 1183.86 which is 14.58% lower the current market price of 1,386.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,190 Cr. market cap, FY2025-2026 high/low of 2,350/1,292, reserves of ₹260 Cr, and liabilities of 296 Cr.
What is the Market Cap of 3B Blackbio DX Ltd?
The Market Cap of 3B Blackbio DX Ltd is 1,190 Cr..
What is the current Stock Price of 3B Blackbio DX Ltd as on 26 October 2025?
The current stock price of 3B Blackbio DX Ltd as on 26 October 2025 is 1,386.
What is the High / Low of 3B Blackbio DX Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of 3B Blackbio DX Ltd stocks is 2,350/1,292.
What is the Stock P/E of 3B Blackbio DX Ltd?
The Stock P/E of 3B Blackbio DX Ltd is 24.3.
What is the Book Value of 3B Blackbio DX Ltd?
The Book Value of 3B Blackbio DX Ltd is 313.
What is the Dividend Yield of 3B Blackbio DX Ltd?
The Dividend Yield of 3B Blackbio DX Ltd is 0.29 %.
What is the ROCE of 3B Blackbio DX Ltd?
The ROCE of 3B Blackbio DX Ltd is 25.8 %.
What is the ROE of 3B Blackbio DX Ltd?
The ROE of 3B Blackbio DX Ltd is 19.4 %.
What is the Face Value of 3B Blackbio DX Ltd?
The Face Value of 3B Blackbio DX Ltd is 10.0.